---
title: "Simcere Partners with Boehringer Ingelheim to Develop Bispecific Antibody for IBD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273859021.md"
datetime: "2026-01-27T14:50:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273859021.md)
  - [en](https://longbridge.com/en/news/273859021.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273859021.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273859021.md) | [繁體中文](https://longbridge.com/zh-HK/news/273859021.md)


# Simcere Partners with Boehringer Ingelheim to Develop Bispecific Antibody for IBD

Simcere Pharmaceutical Group Ltd. has entered into a license and collaboration agreement with Boehringer Ingelheim to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody for the treatment of inflammatory bowel disease (IBD). Under the terms of the agreement, Boehringer Ingelheim receives global rights to the asset, excluding Greater China. Simcere is eligible to receive an upfront payment, as well as milestone payments totaling up to EUR 1,058 million, and royalties on net sales outside Greater China. The partnership aims to accelerate the development of this potential first-in-class treatment to address unmet needs in IBD worldwide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN71842) on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Vertex Pharmaceuticals Says US FDA Approves Label Expansion for Alyftrek, Trikafta](https://longbridge.com/en/news/281365753.md)
- [Samsung Biologics Acquires GSK's Manufacturing Facility in US](https://longbridge.com/en/news/281465578.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/en/news/281346305.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)
- [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/en/news/281174396.md)